Analyst Ratings For Kala Pharmaceuticals Inc (NASDAQ:KALA)
Today, HC Wainwright initiated coverage on Kala Pharmaceuticals Inc (NASDAQ:KALA) with a Buy.
There are 0 sell ratings, 0 hold ratings, 6 buy ratings, 0 strong buy ratings on the stock.
The current consensus rating on Kala Pharmaceuticals Inc (NASDAQ:KALA) is Buy with a consensus target price of $36.00 per share, a potential 192.45% upside.
Some recent analyst ratings include
- 7/23/2018-HC Wainwright initiated coverage with a Buy rating.
- 6/20/2018-Wedbush Reiterated Rating of Outperform.
- 1/25/2018-Wells Fargo & Co Reiterated Rating of Outperform .
- 8/15/2017-Oppenheimer initiated coverage with a Outperform rating.
- 8/14/2017-Bank of America initiated coverage with a Buy rating.
About Kala Pharmaceuticals Inc (NASDAQ:KALA)
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.
Recent Trading Activity for Kala Pharmaceuticals Inc (NASDAQ:KALA)
Shares of Kala Pharmaceuticals Inc closed the previous trading session at 12.31 −0.15 1.20 % with 80600 shares trading hands.